Advances in Neoadjuvant Therapy for Urologic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 2779
Editor
Special Issue Information
Dear Colleagues,
In the last few decades, unprecedented improvements in the knowledge of the biology of genitourinary cancers have led to dramatic changes in the therapeutic landscape of these diseases.
Immune checkpoint inhibitors (ICIs) led to a paradigm shift in the treatment of genitourinary tumors, showing a significant improvement in survival outcomes. However, in other tumors, such as prostate and testis cancer, the role of ICIs remains marginal.
Recently, new targeted therapies, such as tyrosine kinase inhibitors (TKIs), antibody–drug conjugates (ADCs), and anti-FGFR drugs, are revolutionizing the treatment landscape of these tumors, and further studies are currently underway.
The present Special Issue aims to explore the implications of novel treatment strategies and biomarkers in neoadjuvant settings for patients suffering from genitourinary tumors.
Dr. Carlo Messina
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neoadjuvant treatment
- bladder cancer
- prostate cancer
- renal cell carcinoma
- penile cancers
- immunotherapy
- antibody–drug conjugates
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
